Introduction
Standard financial metrics (revenue growth, EBITDA margins, EPS) provide a snapshot of a pharma company's current performance. But pharma is a business where today's financials can be excellent while the company is heading toward a revenue cliff. Healthcare bankers use a set of sector-specific KPIs that look beyond current performance to assess franchise health, pipeline adequacy, and commercial momentum.
Revenue Quality Metrics
Prescription Metrics: TRx and NRx
- TRx and NRx
TRx (total prescriptions) measures the total number of prescriptions dispensed for a product, including new prescriptions and refills. NRx (new prescriptions) measures only first-time prescriptions for the product by a given patient. NRx is the leading indicator of market penetration and physician adoption, while TRx reflects the total installed patient base including chronic-use patients on refills. A product with growing NRx but flat TRx is gaining new patients but losing existing ones. Growing NRx and growing TRx together signals a healthy franchise.
Healthcare bankers track prescription data (available from IQVIA, Symphony Health, and other providers) to assess commercial momentum independently from revenue figures. Prescription trends can diverge from revenue trends because of gross-to-net changes: a product might show flat TRx but declining revenue if GTN deductions are increasing.
Market Share and Share of Voice
Market share (the product's TRx as a percentage of total TRx in the therapeutic category) reveals competitive positioning. A product losing market share even with growing absolute TRx is being outpaced by competitors in a growing market.
Share of voice (the percentage of total promotional spending in the category directed at the product) indicates commercial investment intensity. A product with high share of voice but declining market share may face efficacy or safety disadvantages that marketing cannot overcome.
Pipeline Health Metrics
The Patent Cliff Coverage Ratio
Pipeline Phase Distribution
The distribution of pipeline assets across development phases reveals the timing and probability of future revenue contributions:
| Phase | Count | Expected Value | Time to Revenue |
|---|---|---|---|
| Preclinical | High count desired | Low (5-10% PoS) | 8-12 years |
| Phase I | Moderate count | Low-moderate (10-14% PoS) | 6-10 years |
| Phase II | Critical mass needed | Moderate (15-25% PoS) | 4-7 years |
| Phase III | Most valuable | High (55-65% PoS) | 2-4 years |
| Filed/Approved | Near-commercial | Very high (80-90% PoS) | 0-2 years |
A pharma company with a deep Phase I pipeline but nothing in Phase II or III faces a 4-7 year gap before meaningful new revenue materializes. A company with multiple Phase III assets but an empty early pipeline has near-term coverage but potential long-term vulnerability.
Commercial Metrics
Gross-to-Net Trends
GTN trends (the trajectory of net revenue realization as a percentage of gross revenue) are among the most important commercial KPIs. A widening GTN (increasing discounts as a percentage of gross revenue) signals deteriorating pricing power, increasing PBM leverage, or growing 340B exposure. Pharma companies that disclose net price growth separately from list price growth provide the most useful data for valuation.
R&D Productivity
R&D productivity measures the return on R&D investment. While imprecise (R&D outcomes are lumpy and lag spending by years), several metrics provide directional insight:
- Cost per NME approval: Total R&D spending over a 10-year period divided by the number of new molecular entities approved. Industry average is estimated at $1-2 billion per NME
- Revenue per R&D dollar: NPV of approved products divided by cumulative R&D spending. Higher ratios indicate more productive R&D programs
- Pipeline value per R&D dollar: Total probability-weighted pipeline NPV divided by annual R&D spend
This article concludes the Pharmaceuticals section. The next section covers Biotech, where the business model, valuation methodology, and M&A dynamics are fundamentally different from the pharma companies discussed here.
Free Interview PDF Guide